Oct. 25 at 3:26 AM
$ICU Comparison to Competitors
SeaStar’s SCD therapy is part of a niche but growing field of immunomodulatory extracorporeal therapies. Here’s how it compares:
Company / Therapy Mechanism Target Condition(s) Regulatory Status Differentiator
SeaStar Medical (SCD) Cell-directed immune modulation AKI, Cardiorenal, ESRD, SIRS FDA Breakthrough Device (multiple) Targets activated neutrophils/monocytes
CytoSorbents (CytoSorb) Hemoadsorption of cytokines Sepsis, Cardiac Surgery CE Mark, FDA Emergency Use Broad cytokine removal
ExThera Medical (Seraph 100) Pathogen adsorption Sepsis, COVID-19 CE Mark, FDA Emergency Use Targets pathogens directly
Toraymyxin Endotoxin adsorption Septic shock Approved in Japan, EU Specific to endotoxins